What are the main functions and effects of Bedaquiline/Sneril?

Bedaquiline (Bedaquiline) is a new anti- tuberculosis drug, which belongs to the triazoquinoline class and is mainly used for the treatment of multi-drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). Its unique pharmacological mechanism makes it an effective supplement and innovative option to traditional anti-tuberculosis drugs. Unlike first-line drugs such as isoniazid and rifampin, bedaquiline targets the ATP synthase of Mycobacterium tuberculosis and irreversibly inhibits its activity, blocking bacterial energy synthesis and causing the bacteria to lose their ability to survive. This mechanism can not only kill drug-resistant strains, but also quickly reduce the burden of tuberculosis bacteria in the body in the short term, thereby improving the overall treatment effect in a multi-drug combination regimen.

Clinical practice shows that the addition of bedaquiline can significantly improve the treatment results of MDR-TB patients. In standardized treatment regimens, it is often combined with other second-line anti-tuberculosis drugs such as rifabutin, linezolid or cycloserine to form an effective multi-drug combination, thereby reducing the risk of continued evolution of drug-resistant strains. Compared with traditional treatment, bedaquiline has obvious advantages in shortening the course of treatment, improving the recovery rate, and reducing recurrence. Multiple overseas clinical studies have shown that the disease-free survival rate and improvement rate of lung lesions among patients who received intensive phase treatment with bedaquiline were better than those in the control group who did not use the drug, which also makes it an important component recommended in the treatment guidelines for multi-drug-resistant tuberculosis.

In addition to its potent antibacterial effect, the advantages of bedaquiline in clinical applications include oral administration and good compliance. The treatment cycle for multidrug-resistant tuberculosis is usually long, and patients need to continue to use multiple drugs for several months to a year. Oral bedaquiline is convenient for patients to take for a long time, reducing the discomfort and loss of compliance caused by injectable drugs. At the same time, bedaquiline shows lower drug tolerance issues in combination therapy. Compared with some injectable second-line drugs, its toxic and side effects are more controllable, which is especially important for patients who require long-term treatment.

Reference materials:https://en.wikipedia.org/wiki/Bedaquiline